Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929282 | 1.00 | P4HTM (1.00) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL23488365 | 0.87 | P4HTM (0.77) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL2186639 | 0.87 | P4HTM (0.77) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL19405836 | 0.86 | P4HTM (0.74) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL30222045 | 0.86 | P4HTM (0.75) | P4HTMPLA2G4BFFAR1ALKBH1 | |
| SCHEMBL3504363 | 0.86 | P4HTM (0.75) | P4HTMNR4A2MAOBPARP10CYP4F2 | |
| SCHEMBL20819400 | 0.84 | P4HTM (0.73) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL21588085 | 0.84 | P4HTM (0.73) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL20819382 | 0.84 | P4HTM (0.73) | P4HTMNR4A2NR4A1NR4A3SRD5A2 | |
| SCHEMBL11383635 | 0.84 | P4HTM (0.73) | P4HTMNR4A2NR4A1NR4A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | SIENA BIOTECH S.P.A. (IT) | 2013-08-01 | — | — | US | claimed |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | ANDREINI MATTEO (IT) | 2012-08-23 | — | — | US | claimed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| US-12291522-B2 | Galectin-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-06 | — | — | US | disclosed |
| US-20230303538-A1 | GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-28 | — | — | US | disclosed |
| CN-115768768-A | Galectin-3 inhibitors | 百时美施贵宝公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2021242982-A1 | GALECTIN-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-06-10 | — | — | US | disclosed |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-3418276-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2018-12-26 | — | — | EP | disclosed |
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-1263756-B1 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-02-25 | — | — | EP | disclosed |
| CN-1420881-A | Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL MYERS SQUIBB PHARMACEU (US) | 2003-05-28 | — | — | CN | disclosed |
| US-6495565-B2 | FOR THERAPY OF ACUTE INFECTION, ACUTE PHASE RESPONSE, AGE RELATED MACULAR DEGENERATION, ALCOHOLISM, ANOREXIA, ASTHMA, AUTOIMMUNE DISEASE, AUTOIMMUNE HEPATITIS, BECHET'S DISEASE, CACHEXIA, CALCIUM PYROPHOSPHATE DIHYDRTATE DEPOSITION | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-17 | — | — | US | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| US-4260620-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1981-04-07 | — | — | US | disclosed |
| US-4202901-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-05-13 | — | — | US | disclosed |
| US-4197302-A | HYPOTENSIVE AGENTS, 5-ETHERIFIED, ALSO ESTERS, AMIDES, HYDRAZIDES | CIBA-GEIGY CORPORATION (US) | 1980-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196984-A1 | 3-AMINO-5-PHENYL-56-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | P4HTM 1069/4885NR4A2 685/4885NR4A1 1719/4885 |
| US-20120214806-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINES | BACE2, BACE1, APP | P4HTM 958/4885NR4A2 819/4885NR4A1 2121/4885 |
| US-20230303538-A1 | GALECTIN-3 INHIBITORS | LGALS3, LGALS1, LGALS3BP | P4HTM 4550/4885NR4A2 4282/4885NR4A1 4048/4885 |
| US-12291522-B2 | Galectin-3 inhibitors | LGALS3, LGALS1, LGALS3BP | P4HTM 4550/4885NR4A2 4282/4885NR4A1 4048/4885 |
| US-20210170033-A1 | NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | P4HTM 1793/4885NR4A2 2611/4885NR4A1 4102/4885 |
| US-20210040062-A1 | AZOLE-SUBSTITUTED PYRIDINE COMPOUND | CYP2F1, CYP21A2, CYP11B1 | P4HTM 336/4885NR4A2 1468/4885NR4A1 991/4885 |
| US-20020013341-A1 | Beta-Amino-Acid derivatives as inhibitors of matrix metalloproteases and TNF-Alpha | TNF, XPNPEP1, MMP2 | P4HTM 1703/4885NR4A2 2425/4885NR4A1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.